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 2 
SUMMARY 38 
Breast cancer is a heterogeneous disease. Tumor cells and associated healthy cells form 39 
ecosystems that determine disease progression and response to therapy. To characterize 40 
features of breast cancer ecosystems and their associations to clinical data, we analyzed 144 41 
human breast tumor and 50 non-tumor tissue samples using mass cytometry. The expression of 42 
73 proteins in 26 million cells was evaluated using tumor and immune cell-centric antibody 43 
panels. Tumors displayed individuality in tumor cell composition, including phenotypic 44 
abnormalities and phenotype dominance. Relationship analyses between tumor and immune 45 
cells revealed characteristics of ecosystems related to immunosuppression and poor prognosis. 46 
High frequencies of PD-L1+ tumor-associated macrophages and exhausted T cells were found in 47 
high-grade ER+ and ER- tumors. This large-scale, single-cell atlas deepens our understanding of 48 
breast tumor ecosystems and suggests that an ecosystem-based patient classification will 49 
facilitate the identification of individuals for precision medicine approaches targeting the tumor 50 
and its immunoenvironment. 51 
 52 
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INTRODUCTION 56 
Breast cancer is the major cause of cancer death among women worldwide (Torre et al., 2017). A 57 
major obstacle for implementation of precision medicine is our lack of understanding the breast 58 
cancer ecosystem. Tumor ecosystems are comprised of cancer cells, infiltrating immune cells, 59 
stromal cells, and other cell types together with non-cellular tissue components (McAllister and 60 
Weinberg, 2010). Cancer cells and tumor-associated cells are phenotypically and functionally 61 
heterogeneous due to genetic and non-genetic sources. Targets of current therapies and 62 
therapies under development, including ER, HER2, PI3K, AKT, mTOR, AR, EGFR, PARP, BCL-63 
2, Survivin, CDK4/6, and methyltransferases, are heterogeneously expressed within and between 64 
patients (Marusyk et al., 2012). This heterogeneity equips cancer cells for proliferation, survival, 65 
and invasion and likely underlies differential treatment efficacies (Ramos and Bentires-Alj, 2015). 66 
Recent single-cell genomics and transcriptomics analyses provided insights into intratumor 67 
genomic diversity and intertumor differences in clonal composition, but very few cells and tumors 68 
were analyzed (Chung et al., 2017, Nik-Zainal et al., 2012). In the healthy mammary gland, 69 
phenotypes of normal luminal and myoepithelial (basal) cells are tightly controlled (Visvader and 70 
Stingl, 2014). Luminal cells heterogeneously express ER, PR, and cytokeratins K7, K8, and K18, 71 
while basal cells express K5, K14, and SMA for proper tissue function (Santagata et al., 2014). 72 
 Tumor ecosystems are further shaped by cellular relationships, and strategies targeting 73 
relationships that promote tumor development hold considerable promise (McAllister and 74 
Weinberg, 2010). Examples are immune checkpoint inhibition therapies targeting exhausted and 75 
regulatory T cells (T-regs) (Wherry and Kurachi, 2015; Vargas et al., 2018). T cell exhaustion can 76 
be mediated by tumor cells, tumor-associated macrophages (TAMs), and stromal cells through 77 
activation of the co-inhibitory receptors PD-1, CTLA-4, and TIM-3. T-regs can secrete 78 
immunosuppressive cytokines (Quail and Joyce, 2013). Ongoing clinical trials suggest that the 79 
response rates to checkpoint inhibition therapies in breast cancer are not comparable to those of 80 
melanoma or lung cancer patients, likely due to lower immunogenicity (Dieci et al., 2016). 81 
However, in cohorts selected for patients with PD-L1+ breast tumors, higher overall response 82 
rates were reported (Wein et al., 2018). TAMs can modulate tumor ecosystems either through 83 
immunosuppressive actions (e.g., PD-L1 expression) or by promoting tumor growth, 84 
angiogenesis, and invasion (Cassetta and Pollard, 2018; Quail and Joyce, 2013) and are thus 85 
promising therapeutic targets.  86 
 Given the heterogeneity of cell phenotypes and cellular relationships in breast cancer, 87 
patient classification and treatment should ideally consider the entire cancer ecosystem. Recent 88 
single-cell RNA sequencing studies provided a glimpse into breast cancer immune cell 89 
phenotypic diversity (Azizi et al., 2018; Chung et al., 2017), laying a foundation for studies using 90 
large patient cohorts. Currently, however, breast tumors are stratified for clinical purposes based 91 
on tumor cell expression of ER, PR, HER2, and the proliferation marker Ki-67 (Coates et al., 92 
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2015). These biomarkers serve as surrogates for prognostic gene expression profiles and 93 
categorize tumors as Luminal A (ER+ and/or PR+, HER2-, Ki-67+ <20%), Luminal B (ER+ and/or 94 
PR+, HER2-, Ki-67+ ≥20%), Luminal B-HER2+ (ER+ and/or PR+, HER2+), HER2+ (ER-PR-HER2+), 95 
and triple-negative (TN; ER-PR-HER2-) (Perou et al., 2000). Alternative classification schemes 96 
based on gene expression and genomic alterations were proposed (Curtis et al., 2012). In 97 
addition, pathological tumor grading assesses morphological deviation of tumor tissue and cells 98 
from normal to predict patient prognosis (AJCC, 2017). Although these stratifications have 99 
improved therapy success, patient responses vary within each subtype, demanding a better 100 
characterization of breast cancer ecosystems.  101 
 Here we applied single-cell mass cytometry (Bandura et al., 2009) to millions of cells from 102 
144 human breast tumors covering all clinical subtypes to elucidate the phenotypic diversity and 103 
tumor-immune cell relationships in breast cancer ecosystems. Non-tumor controls comprised 46 104 
samples located juxtaposed to tumor tissue (“juxta-tumoral”) and four mammoplasty samples 105 
from breast cancer-free individuals. Our data revealed vast phenotypic diversity among tumor 106 
and immune cells in breast cancer ecosystems. To quantify aspects of tumor heterogeneity, we 107 
introduced computational scores describing tumor phenotypic abnormality, individuality, and 108 
richness. Each tumor ecosystem was composed of tumor cells with varying phenotypic 109 
abnormalities and tumor cell phenotypes associated with therapy resistance were abundant. We 110 
identified tumor and immune cell phenotypes and phenotype relationships linked to poor 111 
prognosis, immunosuppression, and response to checkpoint inhibitor immunotherapy in high-112 
grade tumors and in ER+ tumors, which are typically not associated with immunogenicity. This 113 




A single-cell proteomic atlas of breast cancer ecosystems 118 
We performed large-scale mass cytometry profiling of 144 prospectively collected tumors, 119 
including 56 Luminal A, 72 Luminal B, six Luminal B-HER2+, one HER2+ and six TN tumors 120 
(Tables S1 and S2) (Coates et al., 2015). Histopathology divided the samples into 106 invasive 121 
ductal, 16 invasive lobular, and 22 mixed/other tumors (Table S2). An automated system was 122 
used to generate single-cell suspensions from all tissue samples (STAR Methods). These 123 
samples and seven breast cancer cell lines were mass-tag barcoded (Zunder et al., 2015), 124 
pooled for antibody staining with 73 antibodies, and simultaneously analyzed by mass cytometry 125 
(Figures 1A and S1A, STAR Methods). An immune cell-centric antibody panel focused on 126 
immune phenotyping and was based on our recent immune cell atlas of clear cell renal cell 127 
carcinoma (ccRCC) (Chevrier et al., 2017) (Table S3). A tumor cell-centric panel was built to 128 
quantify markers that identify mammary cell types, signaling, proliferation, and survival (Table 129 
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S4). Application of our workflow yielded 26 million single-cell profiles with an average of 84.7% 130 
live, non-apoptotic cells per sample (Figures S1B-C).  131 
To ensure high data quality, we confirmed the similarity of marker expression of the 132 
control samples across barcoding plates and of live cell and immune cell frequencies across 133 
antibody panels (Figures S1D-E). Neither sample collection nor processing led to batch effects 134 
(Figures S1F-G, STAR Methods). Minimal spillover between mass detection channels was 135 
corrected using a bead-based compensation workflow (Chevrier et al., 2018). The frequencies of 136 
ER+, PR+, HER2+, and Ki-67+ tumor cells determined by mass cytometry were comparable to the 137 
matched pathological immunohistochemistry scores (Figures S1H-L, STAR Methods). 138 
To visualize the diversity of tumor and non-tumor cells, we generated two-dimensional 139 
graphs using the dimensionality reduction algorithm t-distributed stochastic neighbor embedding 140 
(t-SNE; Van Der Maaten and Hinton, 2008) (Figure 1B; STAR Methods). Most cells were 141 
epithelial (expressing EpCAM, E-Cadherin, and epithelial cytokeratins) or immune (CD45+). 142 
Endothelial cells (CD31+) and fibroblasts (FAP+/-SMA+/-) were less abundant (Figure 1B). 143 
Additional fibroblast subsets (Costa et al., 2018) and adipocytes were likely among the cells 144 
described as “other” (Figure 1C). To compare cell-type frequencies between tumor and non-145 
tumor tissue, we applied the PhenoGraph algorithm (Levine et al., 2015), which partitioned our 146 
high-dimensional single-cell data into 42 clusters (Figures S1M-N, STAR Methods). Marker 147 
expression profiles reliably assigned clusters to cell types (Figures 1C and S1M). Breast tumors 148 
were enriched for epithelial cells and contained fewer endothelial cells and fibroblasts than non-149 
tumor tissues (Figure 1D). Fibroblasts were more abundant in tumors than in juxta-tumoral tissue 150 
(Figures S1O-P). The cell type frequencies varied among and between tumor subtypes with a 151 
higher frequency of immune cells observed in TN and HER2+ samples than in other breast 152 
cancer types (Figures 1E and S1P). 153 
 154 
The immune landscape of breast cancer 155 
T cells and myeloid cells were the most abundant immune cell types in our study; fewer natural 156 
killer (NK) cells, B cells, granulocytes, plasma cells, and plasmacytoid dendritic cells were 157 
detected (Figures 2A, S2A-D). Breast tumors were enriched for T cells and B cells and contained 158 
a lower frequency of NK cells and granulocytes than juxta-tumoral tissue (Figure 2A). There was 159 
considerable inter-patient variation in tumor-associated immune cell frequencies (Figure 2A) as 160 
previously described (Azizi et al., 2018; Chevrier et al., 2017; Lavin et al., 2017). 161 
  T cells and macrophages can exert pro-tumor or anti-tumor activities (Quail and Joyce, 162 
2013). In-depth analyses of T cells by t-SNE and PhenoGraph identified ten CD4+ and ten CD8+ 163 
T cell clusters (T01-T20; Figures 2B-D). Most T cell clusters had an effector memory phenotype 164 
(CD197+, CCR7low, CD45RAlow), and tumor-associated T cells existed as a phenotypic continuum 165 
across the CD4+ and CD8+ lineages (Figures 2D and S2E) (Azizi et al., 2018; Egelston et al., 166 
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2018). Various levels of PD-1 and heterogeneous co-expression of co-inhibitory receptors and 167 
activation markers were detected among CD8+ (T11, T14, T07) and CD4+ T cell clusters (T09, 168 
T13, T18). An increase in PD-1 levels and receptor co-expression likely represent increasingly 169 
exhausted T cell states (Wherry and Kurachi, 2015). PD-1highCD8+ T cells (T11) expressed the 170 
co-inhibitory receptors TIM-3 and CTLA-4 and activation markers HLA-DR and CD38 (Figure 2D). 171 
This phenotype was associated with T cell exhaustion and anti-PD-1 therapy response in 172 
melanoma (Daud et al., 2016; Sade-Feldman et al., 2018). PD-1highCD4+ T cells (T09, T13) were 173 
positive for CTLA-4, CD38, and CD278 but negative for TIM-3 and HLA-DR. PD-1intCD8+ (T07, 174 
T14) and PD-1intCD4+ T cells (T18) were negative for CTLA-4, TIM-3, HLA-DR, and CD38 (Figure 175 
2D). T-regs (T01) were identified based on expression of CD4, FOXP3, CD25, and CTLA-4. T-176 
regs and PD-1highCTLA-4+CD38+ T cells (T09, T11, T13) were enriched in tumors compared to 177 
juxta-tumoral tissue (Figure 2E). The majority of patients showed PD-1+ T cells, which comprised 178 
up to 26.6% of total tumor-associated T cells, but were rare in juxta-tumoral tissue (Figure S2F). 179 
Most PD-1+ T cells were found within the CD8+ compartment (Figure 2F, top panel). However, the 180 
mean expression level of PD-1 was higher in CD4+ than in CD8+ T cells (Figure 2F, bottom 181 
panel). The mean expression level of PD-1 and the PD-1+ T cell frequency correlated in the CD4+ 182 
and CD8+ compartments, supporting the hypothesis that these cells result from T cell expansion 183 
(Figure 2G) (Keren et al., 2018; Li et al., 2018).   184 
 ER- breast cancer subtypes reportedly respond better to immune checkpoint blockade 185 
than ER+ subtypes (Dieci et al., 2016). We observed differences in the T cell landscapes of ER- 186 
and ER+ tumors including a higher frequency of T-regs in ER- disease (Figure 2H). In more than 187 
half of ER- tumors (6/10) but only 12% of ER+ tumors (16/132) over 10% of T cells expressed PD-188 
1 (Figure S2G). Distinct PD-1+ phenotypes were separately enriched: PD-1highCTLA-4+CD38+ T 189 
cells (T09, T11, T13) were more frequent in ER- tumors, whereas PD-1intCTLA-4-CD38- T cells 190 
(T14) were enriched in ER+ tumors (Figure 2H). Many ER+ tumors did, however, show 191 
frequencies of PD-1highCTLA-4+CD38+ T cells and T-regs comparable to or higher than ER- 192 
tumors (Figure 2H). Therefore, our data support that patients with ER- tumors are candidates for 193 
immunotherapy (Dieci et al., 2016) and indicate that a subset of patients with ER+ tumors should 194 
benefit, too.  195 
ER+ tumors can be divided into Luminal A and Luminal B based on low and high 196 
proliferation, respectively. More than 10% of T cells expressed PD-1 in 18% of Luminal B tumors 197 
but only 7% of Luminal A tumors (Figure S2H). PD-1intCTLA-4-CD38- T cells (T07) were more 198 
frequent in Luminal A disease and T-regs were enriched in Luminal B tumors (Figure 2I). We also 199 
observed distinct T cell landscapes in tumors of different grades. PD-1+ T cells accounted for 200 
more than 10% of T cells in 28% of grade 3 tumors, 9% of grade 2 tumors, and 10% of grade 1 201 
tumors (Figure S2I). Grade 3 tumors had more PD-1highCTLA-4+CD38+ T cells (T09, T11) and 202 
fewer PD-1intCTLA-4-CD38- T cells (T07, T14) than tumors of lower grades (Figure S2J). This 203 
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demonstrates that an immunosuppressed T cell landscape is linked to poor prognosis tumors, 204 
including ER-, high proliferation, and high-grade tumors, but is also observed in a subset of ER+ 205 
tumors.  206 
 207 
Breast tumors are enriched for immunosuppressive macrophage phenotypes 208 
To characterize TAM populations, t-SNE and PhenoGraph were applied to all myeloid cells 209 
(Figures 2J and S2D), resulting in 19 myeloid clusters (M01-M19) of five categories: i) CD14-210 
expressing classic (M06, CD14+CD16-) and inflammatory monocytes (M15, CD14intCD16+), ii) 211 
early immigrant macrophages (M03, M11, M13, HLA-DRintCD192+), iii) tissue-resident 212 
macrophages (M08, M09, M16, CD206+HLA-DRint), iv) TAMs (M01, M02, M04, M14, M17, 213 
CD64highHLA-DRhigh), and v) myeloid-derived suppressor cells (MDSCs; M07, M10, M12, HLA-214 
DR-CD38+) (Figures 2K-L). Consistent with previous reports (Azizi et al., 2018; Chevrier et al., 215 
2017), the myeloid phenotypic space differed between tumor and juxta-tumoral regions (Figure 216 
2M). In 80% of tumors at least 10% of myeloid cells were PD-L1+ (Figure S2K) (Cimino-Mathews 217 
et al., 2016). The PD-L1+ TAMs were phenotypically heterogeneous: TAMs in cluster M01 218 
expressed pro-tumor markers CD204, CD206, CD163, and CD38 and anti-tumor marker CD169, 219 
whereas TAMs in M02 expressed CD204, CD169, and intermediate levels of CD163 and CD38, 220 
and TAMs in M17 expressed CD169 and CD38 (Figure 2L). Expression of CD38 is associated 221 
with immunosuppressive macrophages in ccRCC patients and with MDSC-mediated T cell 222 
suppression in colorectal cancer (Chevrier et al., 2017; Karakasheva et al., 2018). Our results 223 
therefore link CD38 and PD-L1 and confirm co-expression of pro- and anti-inflammatory markers 224 
by tumor-associated myeloid cells, including PD-L1+ TAMs (Azizi et al., 2018; Chevrier et al., 225 
2017). Tumors were depleted of tissue-resident macrophages (M08, M09), classical circulating 226 
(M06), and pro-inflammatory (M15) monocytes compared to juxta-tumoral tissue (Figure 2M). 227 
Infiltration by TAMs is associated with aggressive disease (Quail and Joyce, 2013). ER- 228 
tumors contained higher frequencies of M01 and M17 PD-L1+ TAMs and fewer myeloid cells with 229 
M04, M05, M10, or M12 phenotypes compared to ER+ tumors (Figure 2N). A subset of ER+ 230 
tumors had M01 and M02 PD-L1+ TAMs at frequencies comparable to or higher than ER- tumors 231 
(Figures 2N and S2L). Luminal B tumors contained more myeloid cells with M07 or M17 232 
phenotype, less with M04 phenotype, and more PD-L1+ TAMs compared to Luminal A tumors 233 
(Figures 2O and S2M). PD-L1+ TAMs were enriched in grade 3 tumors compared to grade 2 234 
tumors (Figure S2N). Grade 3 tumors contained fewer cells with M04 or M05 phenotype but more 235 
classical monocytes (M06) than lower grade tumors (Figure S2O).  236 
 237 
Tumor epithelial cells are heterogeneous and phenotypically abnormal 238 
The analysis of epithelial cells from tumor and non-tumor tissues (STAR Methods) revealed 239 
bimodal and gradient-like expression of epithelial markers, indicative of many distinct cell 240 
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phenotypes (Figures 3A-B). A consensus clustering approach implemented in PhenoGraph 241 
(Figure S3A; STAR Methods) revealed 45 epithelial clusters (Ep01-Ep45). Hierarchical clustering 242 
classified these into seven luminal groups L1-L7 and two basal groups B1 and B2 based on 243 
marker expression (Figures 3C, S3B-C).  244 
We identified luminal and myoepithelial cells in mammoplasty and juxta-tumoral tissue 245 
based on lineage marker expression patterns (Figures 3C-D, and S3D) (Santagata et al., 2014; 246 
Visvader and Stingl, 2014). Mammary epithelial cell lines confirmed the reliability of these 247 
patterns (Figure 3E) (Neve et al., 2006). About 63% of cells from mammoplasties and 77% of 248 
juxta-tumoral tissue-derived cells were members of groups L1 and L2, characterized by 249 
expression of K7/8/18 and low levels or no ERa (Figures 3C-D). Strong expression of EpCAM 250 
and low levels of adhesion integrin CD49f indicated luminal cell maturity (Figures 3C and S3D) 251 
(Stingl et al., 2001). Proliferating (Ki-67+) non-tumor luminal cells were also identified (Figure 252 
S3E) (Santagata et al., 2014). About 55% of tumor-derived cells were members of groups L1 and 253 
L2, showing that differentiated normal-like luminal cells were abundant in tumor samples.  254 
Groups L3-L7 were dominated by tumor cells (Figure 3C). Group L3 phenotypes showed 255 
high levels of EpCAM and CD49f and low ERa expression (Figures 3C, S3D-F), characteristics of 256 
luminal progenitor cells (Stingl et al., 2001). Group L4 phenotypes displayed high levels of 257 
hormone receptors ERa, PRB, and AR and receptor tyrosine kinases HER2, EGFR, and c-MET 258 
(Figures 3C and S3F), which are involved in tumor cell proliferation and migration (Hsu and 259 
Hung, 2016). Co-expression of these receptors with ERa or HER2 can confer resistance to anti-260 
ERa and anti-HER2 treatments (Hsu and Hung, 2016; Murphy and Dickler, 2016). Strong 261 
receptor tyrosine kinase expression and high levels of the methyltransferase EZH2, its target 262 
H3K27me3, and anti-apoptotic factors Survivin and BCL-2 were observed in group L5 (Figures 263 
3C and S3F). EZH2-induced epigenetic alterations can equip tumor cells for expansion and 264 
invasion (Visvader and Stingl, 2014). Survivin and BCL-2 are associated with cell death evasion 265 
and risk of recurrence in ER+ disease (Parker et al., 2009). Group L6 phenotypes expressed 266 
K7/8/18, ERa, HER2, low levels of CD49f, and high levels of E-Cadherin and CD24 (Figures 3C 267 
and S3F), indicative of luminal cell maturity with ERa and HER2 pathway activity. Group L7 268 
phenotypes were ERa- and HER2-, and expressed HLA-DR+, a surface receptor associated with 269 
tumor immunogenicity (Figures 3C and S3F) (Park et al., 2017). Lack of ERa and HER2 is 270 
associated with resistance to anti-ERa and anti-HER2 treatments. Ki-67+ luminal tumor cells were 271 
found in all luminal cluster groups and were most frequent in group L7 (Figure S3G).  272 
Group L1-L7 phenotypes were differently distributed across tumor subtypes. Group L1 273 
and L2 phenotypes indicative of mature luminal cells and group L4 and L5 phenotypes strongly 274 
expressing ERa were more frequent in Luminal A and B tumors than in HER2+ and TN tumors 275 
(Figure 3F). Proliferating group L7 phenotypes were frequent in several Luminal B, a few Luminal 276 
A, and one TN tumor. Luminal B-HER2+ and HER2+ tumors contained cells from groups L3 and 277 
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L6 (Figure 3F). Many luminal tumors contained fewer K7+ and more K8/18+ cells than adjacent 278 
non-tumor tissue (Figure S3H), suggesting a cytokeratin switch possibly induced by upregulated 279 
PI3K/AKT signaling (Fortier et al., 2010). ERa+ cells varied between 2% - 91% (median 26.7%, 280 
IQR 26.8%) and ERa+AR+ cells varied between 0% - 44% (median 1.7%, IQR 4.3%) in ER+ 281 
tumors. 282 
We identified basal cell phenotypes in group B1 based on expression of K5/14 and 283 
Vimentin and in group B2 based on expression of SMA, Vimentin, and low levels of K5/14. All 284 
basal phenotypes lacked expression of K7/8/18, ERa, and HER2 (Figure 3C). Non-tumor cells 285 
with basal phenotype were likely myoepithelial cells (Figure 3E) (Santagata et al., 2014). In 286 
contrast to juxta-tumoral tissue, myoepithelial cells were sparse in mammoplasty samples, 287 
possibly a consequence of obesity (Chamberlin et al., 2017). Basal-like tumor cells displayed 288 
high levels of Ki-67, EGFR, and tumor suppressor p53 (Figures S3F-G). Overexpression of 289 
EGFR and p53 and lack of ERa and HER2 are characteristics of aggressive, difficult to treat 290 
cancers (Perou et al., 2000). Both basal-like and luminal ERa-HER2-PRBdim phenotypes 291 
expressed high levels of Survivin, indicative of survival pathway activity. The majority of luminal 292 
tumors (126/130) did not contain cells with basal phenotype, consistent with the absence of 293 
myoepithelial cells (Sternlicht and Barsky, 1997). Cells of group B2 were abundant in TN tumors 294 
(Figure 3F) in line with a basal-like molecular subtype (Perou et al., 2000). Tumor cells with basal 295 
phenotype and tumor cells in luminal clusters Ep16 and Ep32 co-expressed EpCAM, E-Cadherin, 296 
and Vimentin, an epithelial-mesenchymal transition (EMT) phenotype associated with tumor cell 297 
invasion and resistance to chemotherapy (Fischer et al, 2015). Tumor cells with EMT phenotype 298 
were found in TN tumors and in several Luminal A and B tumors (Figure S3I). All subtypes except 299 
Luminal A had elevated frequencies of proliferating cells compared to juxta-tumoral tissue (Figure 300 
S3J). Proliferation was strongest in grade 3 tumors (Figure S3K).  301 
 302 
Phenotypic abnormalities and tumor individuality are linked to features of poor prognosis  303 
Tumor cell heterogeneity is believed to drive disease progression and to hamper therapies to 304 
eliminate all cells of the tumor ecosystem (Ramos and Bentires-Alj, 2015). We established three 305 
computational scores to quantify different aspects of tumor heterogeneity (Figure 4A). Phenotypic 306 
abnormality describes the extent of tumor cell phenotypic deviation from non-tumor epithelial 307 
cells. Tumor individuality quantifies the similarity of tumors based on cell phenotypes. Tumor 308 
richness represents the number of different co-existing tumor cell phenotypes within an 309 
ecosystem.  310 
To describe phenotypic abnormalities, we trained an artificial neural network 311 
(autoencoder) (Goodfellow et al., 2016; Hinton and Salakhutdinov, 2006) with multidimensional 312 
single-cell data from the juxta-tumoral samples (STAR Methods). Once trained, the autoencoder 313 
recognized non-tumor epithelial cell phenotypes and calculated a mean squared error (MSE) for 314 
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every tumor cell (Figure S4A). High MSE values indicated high levels of abnormality. The most 315 
abnormal tumor cells were detected in the epithelial cluster groups L6, L7, B1, and B2 (Figure 316 
4B). These included ERa+PRB+HER2+AR+ (Ep42, Ep43) and ERa-PRB+HER2-AR+HLA-DR+ 317 
luminal phenotypes (Ep37, Ep38) and ERa-PRB-HER2-AR- basal-like EMT phenotypes (Ep01, 318 
Ep02, Ep23, Ep24, Ep25). Tumors containing mainly cells from these clusters deviated more 319 
from juxta-tumoral tissue than tumors enriched for cells from groups L1 and L2 (Figures 4C-E). 320 
Phenotypically abnormal cells were enriched in high-grade tumors, most ER- tumors, a subset of 321 
ER+ tumors, and tumors of subtypes with poor prognosis (Figures 4F-H). Phenotypic abnormality 322 
correlated with hypoxia and proliferation marker expression (Figure 4I), reflecting abnormal 323 
growth conditions within the tumor ecosystem (Marusyk et al., 2012). About 25% of CA9+ tumor 324 
cells exhibited an EMT phenotype compared to 4% of CA9- tumor cells. Some juxta-tumoral 325 
tissue samples in our cohort contained phenotypically abnormal cells and high frequencies of 326 
CA9+ or Ki-67+ cells (Figures S4B-C, and Table S5), possibly representing areas of the pre-327 
cancerous lesion ductal carcinoma in situ. 328 
 To assess individuality of tumor ecosystems, we applied a graph-based approach to the 329 
epithelial cell data from all samples (Figure 4A, STAR Methods). The individuality score indicated 330 
whether cells of a sample were more similar to cells of the same sample (score close to 1) or to 331 
cells of other samples (score close to 0) (Figure S4D). Tumors displayed higher individuality 332 
scores than juxta-tumoral tissues (Figure 4J). Importantly, tumor individuality correlated with 333 
phenotypic abnormality (Figure 4K), suggesting that the more tumor cells deviate phenotypically 334 
from non-tumor cells, the less likely they are to be found in tumors from different patients (Figure 335 
S4D). Tumor individuality was more prominent in high-grade tumors and in tumors of Luminal B, 336 
Luminal B-HER2+, or TN subtype (Figure S4E). Individuality varied extensively among ER+ 337 
tumors and correlated with the percentage of ERa+ cells (Figures 4L-M). No association between 338 
individuality and invaded lymph nodes or distant metastasis was detected (Figure S4F). 339 
 To explore the concept of tumor richness (Figure 4A), we calculated the frequency of 340 
each epithelial cell cluster per sample and reported the number of clusters above 1%. All tumors 341 
and non-tumor samples contained cells from multiple clusters (Figure 4N). Remarkably, most 342 
tumors did not display an increased richness compared to non-tumor tissue, and tumor richness 343 
anti-correlated with individuality (Figures 4O-P). In 62 of 144 tumors (43%), at least 50% of all 344 
cells of the tumor belonged to a single cluster, possibly reflecting the expansion of a distinct 345 
cancer cell clone (Figure 4N). This cluster dominance was observed in 58% of grade 3 tumors, 346 
33% of grade 2 tumors, and 35% of grade 1 tumors. Cluster dominance was observed in 51% of 347 
Luminal B, 50% of Luminal B-HER2+, and 67% of TN tumors, but only 29% of Luminal A tumors. 348 
Among the 45 epithelial cell clusters, 37 clusters (82%) comprised at least 50% of all cells in one 349 
or more tumors (Figure 4N). Seven dominant clusters were tumor-specific, and four displayed 350 
high phenotypic abnormality (Figures 4B and S4G).  351 
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Analysis of ten tumors in our cohort that had not considerably regressed despite 352 
neoadjuvant chemotherapy revealed individual phenotype compositions, indicating that different 353 
tumor cell phenotypes had survived therapy (Figure 4Q). These included highly abnormal tumor 354 
cells with ERa-HER2- phenotype (Ep02, Ep37, Ep24) and with ERa+HER2+ phenotype (Ep40, 355 
Ep41) (Figures 4B and 4Q). Two different regions of the same tumor had been collected for four 356 
other patients. In three cases similar phenotype compositions were observed in both regions. In 357 
the fourth tumor, the dominant clone was present in both regions, but at different frequencies, 358 
and one region had a more proliferative character (5% Ki-67+) than the other (0.6% Ki-67+) 359 
(Figure S4H). 360 
 361 
Tumor ecosystem-based classification reveals distinct groups and multiple tumor 362 
singletons 363 
To exemplify a classification that considers all aspects of the tumor ecosystem, we grouped all 364 
tumor and non-tumor samples in our cohort by shared ecosystem patterns. We applied 365 
hierarchical clustering to the frequencies per sample of all epithelial, T cell, and myeloid clusters 366 
identified in this study (Table S5, STAR Methods). The resulting heatmap revealed three groups 367 
containing many tumors (Tu1-Tu3), four groups containing three or four tumors (Tu4-Tu7), 36 368 
tumor singletons, and three groups of non-tumor samples (N1-N3) (Figure 5A). Principal 369 
component analysis identified those clusters explaining the highest variability between the 370 
different groups. Group Tu1 included 42 tumors with high levels of specific epithelial clusters 371 
(Ep14, Ep18, Ep45), T cell clusters (T10, T14, T17), and macrophage clusters (M05, M10, M12) 372 
(Figures 5A, orange rectangle, and 5B). All of these clusters were observed frequently in non-373 
tumor samples, except the PD-1intCTLA-4-CD38- T cell phenotype T14 and the CD38+ MDSC 374 
phenotype M12. The nine tumors of group Tu2 displayed high frequencies of ERadim cells (Ep19; 375 
Figure 5A, red rectangle #1), T-regs (T01), and PD-L1+ TAMs (M01, M02), and intermediate 376 
frequencies of exhausted PD-1highCTLA-4+CD38+ T cells (T09, T11, T13; Figures 5A, red 377 
rectangle #2, and 5B). Group Tu2 tumors had higher individuality and phenotypic abnormality 378 
scores, more proliferating cells, PD-L1+ TAMs, and PD-1+ T cells than tumors of groups Tu1 and 379 
Tu3 (Figures 5C-G). Group Tu3 included 44 tumors with high levels of the ERa+ luminal 380 
phenotypes Ep09 and Ep14 and the ERa- luminal phenotypes Ep17 and Ep18 (Figure 5A, green 381 
rectangles #1). Group Tu3 tumors were enriched for immune cell phenotypes T02, T06, T07, and 382 
M03 (Figures 5A, green rectangle #2, and 5B), which were also common in non-tumor tissue. 383 
Strikingly, groups Tu1-Tu7 were heterogeneous for clinical subtypes and grades (Figures S5A-B).  384 
All mammoplasty samples and 54% of juxta-tumoral samples were found in group N2, 385 
indicating closely related ecosystems (Figure 5A). Similar to non-tumor tissue, the five tumors 386 
found in group N2 contained mainly group L1 and L2 epithelial phenotypes, circulating T cells 387 
(T16), and tissue-resident macrophages (M08) (Figure 5A). All five tumors were of the Luminal A 388 
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subtype and low grade, suggesting that the tumors were phenotypically similar to non-tumor 389 
tissue or that the tumor content was particularly low in these samples. 390 
Many of the tumor singletons had high frequencies of PD-1+ T cell and PD-L1+ TAM 391 
phenotypes associated with immunosuppression (Figures 5A, red arrows, 5B, 5F, and 5G). 392 
Tumor singletons generally did not share tumor cell phenotypes, reflecting high tumor 393 
individuality, had higher phenotypic abnormality scores, and more proliferating cells than tumors 394 
of groups Tu1 and Tu3 (Figures 5C-E). Luminal B-HER2+, HER2+, and TN tumors were either 395 
part of a small tumor group or singletons (Figure 5A).  396 
To identify clusters and cluster combinations with the power to distinguish a given group 397 
from all other samples, we employed a random forest classifier (STAR Methods). The respective 398 
groups were distinguished with accuracy of 94% (Tu1), 83% (Tu2), and 89% (Tu3); multiple 399 
epithelial, T cell, and macrophage clusters drove the separation (Figures S5C-E). Thus, patterns 400 
in both the tumor epithelium and its immunoenvironment contained tumor-stratifying information.  401 
 402 
A breast tumor and its immunoenvironment are interwoven entities and both are important 403 
for classification 404 
Networks of tumor cell and tumor-host cell interactions drive disease progression and are 405 
promising targets for drug intervention (Marusyk et al., 2012; McAllister and Weinberg, 2010). To 406 
systematically elucidate homotypic and heterotypic tumor and immune cell relationships, we 407 
performed pairwise Spearman correlation analyses of the frequencies of all cell phenotype 408 
clusters in all samples (Figures 6A-C, Table S5, STAR Methods). Homotypic epithelial cell 409 
relationships were found between phenotypes from different cluster groups (Figure 6A, black 410 
rectangles). Non-tumor luminal phenotypes such as Ep30 and Ep31 (group L1) were correlated, 411 
whereas tumor-specific phenotypes, such as Ep09 and Ep10 (group L4) or Ep19 and Ep15 412 
(group L2), were often separately enriched, reflecting phenotype dominance and tumor 413 
individuality (Figure 6A). Immunosuppressive phenotypes T-regs (T01), PD-1highCTLA-4+CD38+ 414 
exhausted T cells (T09, T11, T13), and PD-L1+ TAMs (M01, M02, M17) correlated with tumor cell 415 
phenotypes from L4, L5, L6, and B1 (Figure 6B, rectangles without arrows). The frequencies of 416 
non-tumor phenotypes in groups L1 and L2 and cluster Ep39 were inversely linked to these 417 
immunosuppressive phenotypes (Figure 6B, rectangles marked with arrows) but correlated with 418 
PD-1intCTLA-4-CD38- phenotypes T07 and T18 (Figure 6B, rectangles marked with asterisks). 419 
Relationship analysis among tumor-associated immune cells revealed that T-regs and PD-L1+ 420 
TAM phenotypes correlated with PD-1highCTLA-4+CD38+ exhausted T cell phenotypes, 421 
suggesting immunosuppressive interactions (Figure 6C, square and biaxial plots). T-regs and 422 
PD-L1+ TAMs did not or only inversely correlate with PD-1intCTLA-4-CD38- T cell phenotypes 423 
(Figures 6C, rectangles marked by arrows, and S6A). Furthermore, immunosuppressive patterns 424 
correlated with tumor phenotypic abnormality and individuality scores, with hypoxia, and 425 
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proliferation (Figure 6D). We also observed a correlation between immunosuppressive TAMs and 426 
T cells and the abundance of ERa+ cells (Figure 6D), demonstrating that estrogen signaling is a 427 
shaping force in the tumor ecosystem (Straub, 2007). The epithelial-immune relationships in 428 
tumors differed from those of matched juxta-tumoral tissues (Figures S6B-C, STAR Methods); 429 
higher numbers of homotypic epithelial and T cell and heterotypic T cell-TAM relationships were 430 
detected in tumors (Figure S6B-D).  431 
 In our ecosystem-based classification 24% of tumors were singletons. Since the 432 
relationship analyses indicated considerable structure within the tumor immunoenvironment, we 433 
hypothesized that singleton tumors might be grouped based on immunoenvironmental similarities 434 
to guide patient selection for immune-targeted therapies. Repeating the hierarchical clustering 435 
using only the immune cluster frequencies resulted in three tumor immune groups (TIG1-3) 436 
heterogeneous for tumor subtypes. Juxta-tumoral and mammoplasty tissues grouped together 437 
(Figure 6E). Of the previous singleton tumors, 6% were placed into TIG1, 32% in TIG2, and 50% 438 
into TIG3. Tumors in TIG1 were enriched for clusters M05, M10, M12, T10, T14, and T17 (Figure 439 
6E, black rectangle). TIG3 tumors displayed high frequencies of PD-L1+ TAMs (M01, M02, M17) 440 
and PD-1intCTLA-4-CD38- T cells (T14) (Figure 6E, blue rectangles #1) but low levels of PD-441 
1highCTLA-4+CD38+ exhausted T cells (T09, T11, T13) (Figures 6E, blue rectangles #2, and S6E). 442 
In contrast, tumors in TIG2 exhibited high frequencies of T-regs (T01), PD-L1+ TAMs, and PD-443 
1highCTLA-4+CD38+ exhausted T cells (Figure 6E, red rectangles). Therefore, the tumor immune 444 
groups presented distinct relationships among T-regs, PD-1+ T cells, and PD-L1+ TAM 445 
phenotypes (Figure S6E). Juxta-tumoral samples found in TIG1 and TIG3 displayed high 446 
frequencies of PD-1intCTLA-4-CD38- T cells or PD-L1+ TAMs unlike other non-tumor samples 447 
(Figure 6E). In four of the five patients with juxta-tumoral tissue in TIG1 or TIG3, lymph nodes 448 
near the tumor had been invaded, suggesting that these phenotypes resulted from a tumor-449 
associated immune response. 450 
Tumors of different subtypes, including ER+ and ER- tumors, grouped in TIG2, raising the 451 
question whether those immune cells abundant in TIG2 were localized proximally in the tumor 452 
ecosystem. We assessed the spatial distribution of PD-L1+ TAMs and PD-1+ and PD1+CTLA-4+ T 453 
cells in tissue sections of TIG2 tumors by immunofluorescence imaging (STAR Methods) and 454 
found these cells both in the tumor stroma and within tumor epithelium in ER+ and ER- disease 455 
(Figures 6F and S6F). The TIG2 tumors had higher phenotypic abnormality scores than TIG1 and 456 
TIG3 tumors (Figure 6G), suggesting that tumor phenotypic deviation from non-tumor tissue is 457 
associated with changes in the tumor immune landscape. TIG2 tumors also had higher 458 
individuality scores than TIG1 and TIG3 tumors and revealed unique tumor cell phenotype 459 
compositions (Figures 6H-I). All TIG2 tumors contained ERa- cells, ranging from 98% to 15% of 460 
the tumor cell population. Among ERa- cells, we found EMT phenotypes (Ep01, Ep02, Ep16, 461 
Ep23-25, Ep32) in 61% of TIG2 tumors and HLA-DR+ phenotypes (Ep01, Ep37, Ep38) in 39% of 462 
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TIG2 tumors (Figure 6I). ERa+ phenotypes were mainly from groups L4 (Ep07-11) and L5 (Ep26-463 
29) and co-expressed PRB, HER2, and AR with high levels of pro-survival BCL-2 and Survivin. 464 
Thus, in addition to an immunosuppressive environment, TIG2 tumor ecosystems contained 465 
multiple tumor cell populations with potential to escape common cancer therapies.  466 
 467 
DISCUSSION 468 
Communication between heterogeneous tumor cells, infiltrating T cells, and macrophages shapes 469 
the breast cancer ecosystem with impact on disease progression and clinical outcome (Marusyk 470 
et al., 2012; Quail and Joyce, 2013). We constructed an extensive single-cell atlas of human 471 
breast cancer ecosystems by large-scale mass cytometry profiling of 26 million cells from 144 472 
tumors, 46 juxta-tumoral samples, and tissue from four reduction mammoplasties. This atlas 473 
reveals vast phenotypic diversity of mammary epithelial and immune cells, phenotypic 474 
abnormalities of tumor cells, and tumor individuality and highlights tumor-immune cell 475 
relationships enabling an ecosystem-based patient classification.  476 
 Most cases in our study were luminal ER+ breast cancers. Despite generally favorable 477 
prognosis, about 30% of patients with ER+ disease develop therapy resistance and metastases 478 
(Reinert and Barrios, 2015). We found that tumor-derived epithelial cells were phenotypically 479 
much more diverse than cells from non-tumor tissue. Tumors of all clinical subtypes displayed 480 
striking individuality in cellular phenotypic composition. These findings might underlie the 481 
differential treatment responses and relapse rates among ER+ breast cancer patients. Although 482 
multiple tumor cell phenotypes co-existed in all tumor ecosystems, frequently one phenotype was 483 
dominant, possibly reflecting the expansion of the fittest tumor subclone as suggested by 484 
genomics (Nik-Zainal et al., 2012). Phenotype dominance can be particularly important for 485 
disease progression if associated with resistance, such as the dominant ERa-HER2-Survivinhigh 486 
phenotypes we found in tumors resistant to neoadjuvant chemotherapy. Phenotypic abnormality 487 
scores were higher for tumor cells of Luminal B, Luminal B-HER2+, TN, and grade 3 tumors than 488 
of Luminal A and lower grades. Given that HER2+ and TN tumors were underrepresented in our 489 
cohort, we expect that expanded analyses of these subtypes will also reveal tumor cell 490 
heterogeneity and tumor individuality as apparent in ER+ tumors.  491 
 Single-cell RNA sequencing of a few tumors suggested that tumor-associated T cells and 492 
myeloid cells are phenotypically diverse (Azizi et al., 2018; Chung et al., 2017), which is 493 
supported by our analysis of a large cohort. We found that PD-1+ T cells and PD-L1+ TAMs were 494 
common in all breast cancer subtypes (Buisseret et al., 2017). Receptors relevant to T cell 495 
exhaustion (PD-1, CTLA-4, TIM-3) and activation (HLA-DR, CD38) as well as pro-tumor (CD204, 496 
CD206, CD163) and anti-tumor TAM markers (CD38, CD169) were heterogeneously expressed, 497 
reminiscent of findings in breast cancer and ccRCC (Azizi et al., 2018; Chevrier et al., 2017). 498 
Recent work indicated that PD-1+ T cells follow a gradient of dysfunction ranging from low to high 499 
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exhaustion (Li et al., 2018; Sade-Feldman et al., 2018; Wherry and Kurachi, 2015). Our data 500 
confirmed a continuum of T cell exhaustion states linked to increasing PD-1 levels. We found 501 
different combinations of immune checkpoint molecules associated with high PD-1 expression in 502 
both CD4+ and CD8+ T cell populations and identified CD38 as a marker of T cell exhaustion in 503 
breast cancer. Immunosuppressive T cell and TAM phenotypes correlated with tumor-specific 504 
luminal ERa+ and ERa- phenotypes that expressed specific receptor tyrosine kinases and pro-505 
survival proteins. Since interactions between tumor cells, T cells, and TAMs are promising targets 506 
for therapy (Quail and Joyce, 2013), follow-up experiments should elucidate the functional roles 507 
of distinct tumor and immune cell populations in breast cancer ecosystems. 508 
Our data revealed that the frequency of ERa+ cells in ER+ tumors was linked to tumor 509 
individuality. In Luminal B tumors, the frequency of ERa+ cells correlated with PD-L1+ TAMs and 510 
exhausted T cell phenotypes, supporting the notion that hormone receptor signaling shapes the 511 
tumor ecosystem (Straub, 2007). The success of immune checkpoint therapy in ER+ breast 512 
cancer patients has been limited (Shih et al., 2014). Here, we showed that 18% of Luminal B 513 
tumors exhibited patterns of strong T cell exhaustion akin to ER- tumors, suggesting that some 514 
ER+ patients could benefit from neoadjuvant or early adjuvant anti-PD-1/PD-L1 therapy targeting 515 
the primary tumor (Wein et al., 2018). Our study identified patterns within the tumor and immune 516 
ecosystem that are tumor-stratifying independent of subtype and grade. Therefore, assessing the 517 
entire cancer ecosystem should be considered for the design of precision therapies targeting the 518 
tumor and its immunoenvironment and for patient selection for immunotherapy clinical trials. 519 
Further studies are needed to confirm this suggestion. 520 
 Our mass cytometry approach has limitations. First, antibody choices might bias 521 
phenotyping. Antibodies in our tumor panel were selected based on studies delineating mammary 522 
epithelial cell states, gene expression, and protein signatures enriched in breast cancer subtypes 523 
(Neve et al., 2006; Parker et al., 2009; Perou et al., 2000; Santagata et al., 2014). The immune 524 
antibody selections were based on our recent ccRCC immune atlas (Chevrier et al., 2017). All 525 
antibodies were thoroughly validated. Second, tissue dissociation into single-cell suspensions 526 
potentially alters cell-surface molecules. The recapitulation of known cell phenotypes using our 527 
panels indicates small effects (Chevrier et al., 2017). Third, data-driven clustering is sensitive to 528 
the choice of clustering parameters. PhenoGraph is a reproducible single-cell clustering method 529 
(Weber and Robinson, 2016) and yielded epithelial and immune clusters that recapitulated known 530 
mammary epithelial, T cell, and TAM phenotypes. Spatial context and functional roles of these 531 
phenotypes must be addressed in additional experiments (Angelo et al., 2014; Giesen et al., 532 
2014). Fourth, although our tumor samples were of about 0.125 cm3 volume, which is much 533 
larger than volumes typically analyzed in pathology studies, tumor regions might differ. Fifth, our 534 
ecosystem-based patient grouping is a function of the measured markers and the patient cohort. 535 
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Since our samples were collected prospectively, relationship analysis to clinical outcome or 536 
treatment response was not possible. 537 
 New treatment approaches are needed to increase the success of breast cancer precision 538 
medicine. A first step is to comprehensively describe the complex cellular and phenotypic 539 
diversity of tumor ecosystems and the relationships among its components for a large number of 540 
patients. Here we provide such an atlas of breast cancer ecosystems. This atlas will be a 541 
valuable resource for future research to identify clinically relevant cell phenotypes and 542 
relationships in the tumor ecosystem for patient stratification and precision medicine applications. 543 
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FIGURE LEGENDS 792 
Figure 1. A single-cell proteomic atlas of breast cancer ecosystems. (A) Experimental 793 
approach. (B) t-SNE plots of EpCAM, CD45, CD31, and FAP expression in 58,000 cells from all 794 
samples using a 0 to 1 normalization. (C) t-SNE as in B) colored by cell type. (D and E) 795 
Frequencies of live epithelial cells, immune cells, endothelial cells, and fibroblasts for D) 796 
mammoplasty (M), juxta-tumoral (JT), and tumor (T) samples and E) tumor subtypes. Wilcoxon 797 
rank-sum test was used for statistical analysis. * p<0.05, ** p<0.01, *** p<0.001. 798 
 799 
Figure 2. The breast cancer immune landscape. (A) Frequencies of selected immune cell 800 
types in juxta-tumoral and tumor samples. (B) t-SNE plots of the normalized marker expression of 801 
40,000 T cells from all samples. (C) t-SNE of T cells colored by PhenoGraph cluster. (D) 802 
Heatmap of normalized T cell marker expression for 20 T cell clusters. CM, central memory; 803 
Eff/Mem, effector and memory; Reg, regulatory; PD-1, PD-1+. (E) Boxplots showing the 804 
frequencies of the CD4+ (left) and CD8+ T cell clusters (right) in juxta-tumoral and tumor samples. 805 
(F) PD-1+ T cell frequency (top) and mean PD-1 expression (bottom) among tumor-derived CD4+ 806 
and CD8+ T cells. (G) Comparison of the PD-1+ T cell frequency and mean PD-1 expression for 807 
CD8+ (top) and CD4+ T cells (bottom). (H and I) Frequencies of selected T cell clusters in H) ER+ 808 
and ER- tumors and I) Luminal A and B tumors. (J) t-SNE plots of normalized marker expression 809 
of 40,000 myeloid cells from all samples. (K) t-SNE of myeloid cells colored by cluster. (L) 810 
Heatmap of normalized myeloid marker expression for 19 myeloid clusters. Mono, monocyte; T.-811 
res, tissue-resident; E. im., early immigrant; TAM, tumor-associated macrophage; MDSC, 812 
myeloid derived suppressor cells. (M) Frequencies of the myeloid clusters in juxta-tumoral and 813 
tumor samples. (N and O) Frequencies of the indicated myeloid clusters in N) ER+ and ER- 814 
tumors and O) Luminal A and B tumors. Wilcoxon rank-sum test was used for statistical analysis. 815 
* p<0.05, ** p<0.01, *** p<0.001.  816 
 817 
Figure 3. Tumor cell phenotypic landscape in breast cancer. (A) t-SNE plots of normalized 818 
marker expression of 180,000 epithelial cells from all samples. (B) t-SNE highlighting the 819 
distribution of cells from tumor, juxta-tumoral, and mammoplasty tissue. (C) Heatmap of 820 
normalized tumor cell marker expression for 45 epithelial clusters (left). Percentage and total 821 
number of cells from mammoplasty (M), juxta-tumoral (JT), and tumor (T) tissue for each cluster 822 
(right). (D and E) Histograms of the expression of epithelial lineage markers in D) cells derived 823 
from juxta-tumoral tissue and E) cell lines. (F) Frequencies of cells of individual cluster groups by 824 
tumor subtype. Wilcoxon rank-sum test was used for statistical analysis. * p<0.05, ** p<0.01, *** 825 
p<0.001. 826 
 827 
Figure 4. Molecular phenotypic abnormalities and tumor individuality are linked to features 828 
of poor prognosis. (A) Phenotypic abnormality, individuality, and richness shown schematically 829 
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using hypothetical phenotypes (shape) and tumors (color). (B) Phenotypic abnormality scores of 830 
all epithelial clusters. (C) Phenotypic abnormality scores of tumors and the median score of juxta-831 
tumoral samples. (D and E) Stacked histograms of D) frequencies of cells per epithelial cluster 832 
group per tumor ordered by increasing phenotypic abnormality and E) the average frequencies 833 
for juxta-tumoral tissue. (F-H) Tumor phenotypic abnormality scores by F) grade, G) ER status, 834 
and H) subtype. (I) Phenotypic abnormality scores versus the percentage of Ki-67+ and CA9+ 835 
cells for tumors. (J) Individuality scores for juxta-tumoral (JT) and tumor (T) tissue. (K) 836 
Individuality scores versus phenotypic abnormality scores for tumors. (L) Individuality scores for 837 
ER+ and ER- tumors. (M) Individuality scores versus the ERa+ cell frequency for ER+ tumors. (N) 838 
Heatmap of presence and proportion of the 45 epithelial clusters for all samples. (O) Richness 839 
scores for mammoplasty (M), juxta-tumoral (JT), and tumor (T) samples. (P) Individuality scores 840 
versus richness scores for tumors. (Q) Cluster frequency map for ten tumors that had not 841 
regressed despite neoadjuvant therapy. Wilcoxon rank-sum test was used for statistical analysis. 842 
* p<0.05, ** p<0.01, *** p<0.001.  843 
 844 
Figure 5. Relationships in the tumor ecosystem correlate with features of disease 845 
progression. (A) Heatmap of frequencies of epithelial, T cell, and myeloid PhenoGraph clusters 846 
in mammoplasty, juxta-tumoral, and tumor tissues. For tumors, the subtype and grade are 847 
indicated by color. Cosine distance and average linkage were used. (B) Biplots of first two 848 
principal components (PC) of cluster frequencies. Dots represent samples colored by group (top). 849 
The arrow length and direction indicate the importance of the cluster to the PC (bottom). (C-G) 850 
Boxplots of C) individuality and D) phenotypic abnormality scores and frequencies of E) Ki-67+ 851 
cells, F) PD-L1+ macrophages, and G) PD-1+ T cells by group. Wilcoxon rank-sum test was used 852 
for statistical analysis. * p<0.05, ** p<0.01, *** p<0.001. 853 
 854 
Figure 6. Breast tumors and their immunoenvironment are interwoven entities. (A-C) 855 
Spearman correlation analyses using the frequencies of A) epithelial clusters, B) T cell, myeloid, 856 
and epithelial clusters, and C) T cell and myeloid clusters in all samples. Euclidean distance and 857 
average linkage were used (upper panels). Frequencies of selected clusters in juxta-tumoral and 858 
tumor samples (lower panels). (D) Spearman correlation analysis of T cell and myeloid cluster 859 
frequencies with phenotypic abnormality and individuality scores and frequencies of ERa+, CA9+, 860 
and Ki-67+ cells in tumors. (E) Heatmap of frequencies of T cell and myeloid clusters in all 861 
samples by hierarchical clustering using cosine distance and average linkage. For tumors, the 862 
subtype, grade, and three main groups Tu1-3 from Figure 5A are indicated by color. (F) Pseudo-863 
brightfield images of immunofluorescence staining of indicated tumor samples. Arrowheads 864 
indicate PD-1+CTLA-4+ T cells (left) or PD-L1+ TAMs (right). Scale bar, 25 µm. (G and H) 865 
Boxplots of G) phenotypic abnormality and H) individuality scores for tumors in tumor immune 866 
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groups TIG1-3. (I) Cluster frequency map for tumors in TIG2. Tumors and epithelial clusters were 867 
sorted by increasing phenotypic abnormality score. A cutoff of p≤0.01 was used in panels A-D. 868 
Wilcoxon rank-sum test was used for panels G and H. * p<0.05, ** p<0.01, *** p<0.001. 869 
 870 
Figure S1. Cell type identification for a single-cell atlas of breast cancer, Related to Figure 871 
1. (A) Antibody staining strategy. (B) Viable cell frequencies of mammoplasty (M), juxta-tumoral 872 
(JT), and tumor (T) samples. (C) Gating strategy used to isolate live, non-apoptotic cells without 873 
gadolinium background staining. (D) Correlation of the intensity of measured markers in cell lines 874 
between barcoding plates. (E) Correlation of live cell and immune cell frequency of the same 875 
tumor samples between staining panels. (F and G) Correlations between principal components 876 
and F) marker abundances and G) possible experimental confounders. (H) Histograms showing 877 
the expression of ERa, PRB, and HER2 in breast cancer cell lines, single tumors, and cells from 878 
all tumors combined. (I and J) Comparison of the percentages of receptor-positive cells in tumors 879 
to pathological receptor status. (K) Gate for Ki-67+ cells. (L) Spearman correlation of the 880 
percentages of Ki-67+ cells determined by immunohistochemistry versus mass cytometry. (M) 881 
Heatmap showing normalized marker expression for the cell type PhenoGraph clusters. (N) t-882 
SNE plot colored by cluster. (O) Gating strategy to identify fibroblast subsets based on FAP and 883 
SMA. (P) Fibroblast subset frequencies in mammoplasty (M), juxta-tumoral (JT), and tumor (T) 884 
tissues (left) and by tumor subtype (right).  885 
 886 
Figure S2. Immune cell phenotyping in breast tumor and non-tumor tissue, Related to 887 
Figure 2. (A) Gate for immune cells. (B) t-SNE plots of normalized expression of markers used to 888 
identify the main immune cell types among 40,000 representative immune cells of all samples. 889 
(C) t-SNE plot of immune cells colored by cluster. (D) Heatmap of normalized marker expression 890 
for 27 clusters. NK cells, natural killer cells; pDCs, plasmacytoid dendritic cells. (E) Diffusion 891 
maps showing the CD4+ and CD8+ T cell clusters as a phenotypic continuum. T-regs were 892 
omitted. (F-I) PD-1+ T cell frequencies in F) juxta-tumoral and tumor samples, G) ER+ and ER- 893 
tumors, H) juxta-tumoral tissue and tumors by subtype, and I) tumors by grade. (J) T cell cluster 894 
frequencies in tumors by grade. (K-N) PD-L1+ TAM frequencies in K) juxta-tumoral and tumor 895 
samples, L) ER+ and ER- tumors, M) juxta-tumoral tissue and tumors by subtype, and N) tumors 896 
by grade. (O) Myeloid cluster frequencies in tumors by grade. Wilcoxon rank-sum test was used 897 
for statistical analysis. * p<0.05, ** p<0.01, *** p<0.001.  898 
 899 
Figure S3. In-depth analysis of breast tumor cell phenotypes, Related to Figure 3. (A) 900 
Adjusted Rand index (ARI) values for 100 independent PhenoGraph runs using k=100. Each 901 
boxplot corresponds to the distribution of the ARI between each run and all other runs. (B and C) 902 
t-SNE plots of epithelial cells colored by B) cluster and C) cluster group as defined by hierarchical 903 
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clustering. (D) Biaxial plots showing luminal progenitor (LP, blue), luminal differentiated (L, 904 
green), and basal cells (B, red). (E) Expression of K8/18, K7, K5, K14, ERa, and Ki-67 in clusters 905 
Ep31 (top) and Ep39 (bottom) of juxta-tumoral tissue-derived cells. (F) Histograms showing the 906 
expression of epithelial markers in tumor-derived cells by cluster group. (G) Expression of Ki-67 907 
and EpCAM in tumor-derived cells by cluster group. (H) Percentages of K14+, K5+, K7+, and 908 
K8/18+ cells in juxta-tumoral and tumor samples by subtype. (I) Percentage of cells with EMT 909 
phenotype in tumors by subtype. (J and K) Percentage of Ki-67+ cells in juxta-tumoral and tumor 910 
samples by J) subtype and K) grade. Wilcoxon rank-sum test was used for statistical analysis. * 911 
p<0.05, ** p<0.01, *** p<0.001.  912 
 913 
Figure S4. Phenotypic abnormality and individuality of tumor and non-tumor tissue 914 
samples, Related to Figure 4. (A) Computation of phenotypic abnormality scores using an 915 
autoencoder trained with juxta-tumoral tissue-derived "normal-like" cells. Tumor phenotypic 916 
abnormality represents the median Mean Squared Error of all cells of a tumor. (B) Barplot of the 917 
phenotypic abnormality scores of mammoplasty and juxta-tumoral tissues and stacked histogram 918 
of the frequencies of cells per epithelial cluster group per sample. (C) Phenotypic abnormality 919 
scores for mammoplasty (M), juxta-tumoral (JT), and tumor (T) samples. (D) Computation of 920 
tumor individuality scores using a k-nearest neighbor graph, where cells of all tumors are grouped 921 
based on their phenotype. (E) Tumor individuality scores by grade and subtype. (F) Tumor 922 
individuality scores by lymph node status and distant metastasis. (G) Diagram of epithelial 923 
clusters that are dominant (D, >50% of all cells of a sample) or tumor specific (T). (H) Cluster 924 
frequency map showing tumors for which two areas of the same tumor were sampled. Wilcoxon 925 
rank-sum test was used for statistical analysis. * p<0.05, ** p<0.01, *** p<0.001. 926 
 927 
Figure S5. The importance of tumor and immune phenotypes for tumor grouping, Related 928 
to Figure 5. (A and B) Biaxial plot of the first two principal components of the analysis shown in 929 
Figure 5B. A) Dots represent tumor samples colored by group. B) Dots represent tumor samples 930 
colored by subtype (top) and grade (bottom). (C-E) The importance of epithelial, T cell, and 931 
myeloid clusters for predicting whether tumors belong to group C) Tu1, D) Tu2, or E) Tu3 using 932 
random forest classification. 933 
 934 
Figure S6. In-depth analysis of relationships in the tumor ecosystem, Related to Figure 6. 935 
(A) Frequencies of selected T cell clusters for juxta-tumoral and tumor samples. (B) Chord 936 
diagrams of the relationships between T cell, myeloid, and epithelial clusters in tumors and 937 
matched juxta-tumoral tissue for 41 patients (p≤0.001). (C) Frequencies of selected clusters that 938 
differed in correlation between tumor and juxta-tumoral tissue. (D) Absolute number of 939 
correlations between clusters for juxta-tumoral (JT) and tumor (T) tissue and table of the fold 940 
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change between JT and T tissue. (E) Frequency of T cell and TAM phenotypes associated with 941 
immunosuppression for TIG1-3. (F) Pseudo-brightfield images of EpCAM and pan cytokeratin on 942 
tumor tissue. Rectangles highlight the areas shown at higher magnification in Figure 6E. Scale 943 
bar, 50 µm. Spearman correlation and Wilcoxon rank-sum test were used for statistical analysis. * 944 
p<0.05, ** p<0.01, *** p<0.001. 945 
 946 
Table S1. Summary of clinical features, Related to Figure 1 947 
Table S2. Clinical features per patient, Related to Figure 1 948 
Table S3. Immune-centric panel, Related to Figures 1 and 2 949 
Table S4. Tumor-centric panel, Related to Figures 1 and 3 950 
Table S5. Phenotype frequencies, Related to Figures 4-6  951 
Table S6. Immunofluorescence panel, Related to Figure 6   952 
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STAR METHODS 953 
 954 
 955 
CONTACT FOR REAGENT AND RESOURCE SHARING 956 
 957 
Further information and requests for resources and reagents should be directed to and will be fulfilled by 958 
the lead contact Bernd Bodenmiller (bernd.bodenmiller@imls.uzh.ch). 959 
 960 
 961 
EXPERIMENTAL MODEL AND SUBJECT DETAILS 962 
 963 
Clinical samples 964 
Primary mammary gland tissue and health-related data were collected after obtaining written informed 965 
consent from patients at the University Hospital Basel (Switzerland), the University Hospital Zurich 966 
(Switzerland), and in collaboration with the Patient's Tumor Bank of Hope (PATH, Germany) at the breast 967 
cancer centers at St. Johannes Hospital Dortmund and Institute of Pathology at Josefshaus (Germany) and 968 
the University Hospital Giessen and Marburg, Marburg site (Germany). Tissue and health-related data 969 
were collected under approval of the Ethics Committee Northwest/Central Switzerland (#2016-00067), the 970 
Ethics Committee Zurich (#2016-00215), and the faculty of medicine ethics committee at Friedrich-971 
Wilhelms-University Bonn (#255/06). Certified pathologists with extensive experience in preparation and 972 
analysis of breast cancer surgery resectates for diagnostics and research performed pathological staging 973 
for the tumor cohort in this study. Tumor histology, grading, and expression assessment of standard clinical 974 
biomarkers (ER, PR, HER2, Ki-67) were determined at the time of diagnostic pathological work-up 975 
according to the current ASCO/CAP recommendations (Rakha et al., 2014) and are reported in Table S2. 976 
Areas of tumor in the surgery resectates were identified macroscopically prior to sample-taking or 977 
microscopically in fast frozen section analyses. Part of the tumor was formalin cross-linked, embedded in 978 
paraffin, and stained with hematoxylin and eosin and if necessary with standard immunohistochemistry 979 
(IHC) procedures as part of standard diagnostics. For mass cytometry analysis, a tissue sample of about 980 
5x5x5 mm (about 0.125 cm3 volume) was taken prior to paraffin embedding, thus the tumor area processed 981 
for mass cytometry analysis was spatially separate from the tumor area stained for prognostic and 982 
predictive biomarkers. However, the pathologists selected a research sample for this study that was 983 
macroscopically representative of the whole tumor based on many years of experience. From the clinical 984 
perspective, the presence of DCIS is of less importance for diagnosis than detection of tumor invasiveness, 985 
and invasive tumor tissues were chosen as tumor-representative samples for this study. It is likely that 986 
DCIS surrounding the tumor was also sampled and possible that some DCIS was present in non-987 
cancerous tissue juxtaposed to the tumor. This might underlie the grouping of some juxta-tumoral tissue 988 
samples with their matched tumor in Figure 5A. Since the specific tissue areas used in this study could not 989 
be examined by frozen section or hematoxylin and eosin because they were dissociated during the mass 990 
cytometry workflow, we unfortunately do not know whether and how much DCIS was present in each of the 991 
samples. We have an indication based on the pathological histology analysis; see notes in Table S2. It is 992 
highly unlikely, however, that extensive areas of DCIS in the non-cancerous juxta-tumoral tissue were 993 
overlooked preoperatively, since the patients underwent extensive imaging of the breast before surgery, 994 
and no abnormalities were noted. The small differences between the percentages of cells positive for ER, 995 
PR, HER2, and Ki-67 as assessed by pathological IHC compared to the mass cytometry analysis (Figures 996 
S1I and S1J) are likely caused by usage of differences in antibody clones, in assay sensitivities, and in 997 
sampled tumor volumes (mass cytometry, large volume about 0.125 cm3; IHC, small volume). Tumor 998 
subtype definitions in this study were as follows: Luminal A (ER+ and/or PR+, HER2-, Ki-67+ <20%), Luminal 999 
B (ER+ and/or PR+, HER2-, Ki-67+ ≥20%), Luminal B-HER2+ (ER+ and/or PR+, HER2+), HER2+ (ER-PR-1000 
HER2+), and triple negative (TN; ER-PR-HER2-). Some tumor ecosystems grouped together with juxta-1001 
tumoral and mammoplasty samples in Figure 5A. These were of Luminal A subtype and low grade, 1002 
possibly reflecting that the tumor was phenotypically similar to non-cancerous tissue or that the tumor 1003 
content was particularly low in these samples. Ten patients had received neoadjuvant (NA) chemotherapy 1004 
prior to sample collection for this study including one of 56 Luminal A, five of 72 Luminal B, two of six 1005 
Luminal B-HER2+, and two of six TN patients (Table S2). We did not see any significant difference between 1006 
tumors from NA-treated patients and tumors from untreated patients in terms of cell type frequency, 1007 
epithelial and immune phenotype frequencies, phenotypic abnormality, or individuality. 1008 
 1009 
Cell lines  1010 
Human mammary epithelial cell lines were obtained from the American Type Culture Collection (ATCC) 1011 
and cultured according to ATCC recommendations. Cell lines included MCF-10A, MDA-MB-134-VI, MDA-1012 
MB-231, MDA-MB-453, SK-BR-3, and ZR-75-1. Fibroblasts were a gift from the laboratory of Prof. Silvio 1013 
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Hemmi at the University of Zurich and were cultured in DMEM medium (Sigma Aldrich) supplemented with 1014 
2 mM L-glutamine, 1 mM sodium pyruvate, and 10% fetal bovine serum (FBS). Peripheral blood 1015 
mononuclear cells (PBMCs) from healthy donors were obtained from the Zurich Blood Transfusion Service 1016 
and were isolated by histopaque (Sigma Aldrich) density gradient centrifugation.  1017 
 1018 
 1019 
METHOD DETAILS 1020 
 1021 
Tissue preparation  1022 
Following surgical resection, fresh tissue samples were immediately transferred to pre-cooled MACS 1023 
Tissue Storage Solution (Miltenyi Biotec) and were shipped at 4 °C. Tissue processing was completed 1024 
within 24 hours of collection. For dissociation, the tissue was minced using surgical scalpels and further 1025 
disintegrated using the Tumor Dissociation Kit, human (Miltenyi Biotech) and the gentleMACS Dissociator 1026 
(Miltenyi Biotech) according to manufacturer's instructions. The resulting single-cell suspension was filtered 1027 
sequentially through sterile 70-µm and 40-µm cell strainers. The cell suspension was stained for viability 1028 
with 25 µM cisplatin (Enzo Life Sciences) in a 1-min pulse before quenching with 10% FBS. Cells were 1029 
then fixed with 1.6% paraformaldehyde (PFA, Electron Microscopy Sciences) for 10 min at room 1030 
temperature and stored at -80 °C. 1031 
 1032 
Mass-tag cellular barcoding 1033 
To minimize inter-sample staining variation, we applied mass-tag barcoding to fixed cells (Zunder et al., 1034 
2015). A 126-well barcoding scheme composed of unique combinations of four out of nine barcoding 1035 
metals was used for this study; metals included palladium (105Pd, 106Pd, 108Pd, 110Pd, Fluidigm) conjugated 1036 
to bromoacetamidobenzyl-EDTA (Dojindo) as well as indium (113In and 115In, Fluidigm), yttrium, rhodium, 1037 
and bismuth (89Y, 103Rh, 209Bi, Sigma Aldrich) conjugated to maleimido-mono-amide-DOTA (Macrocyclics). 1038 
The concentrations were adjusted to 20 nM (209Bi), 100 nM (105-110Pd, 115In, 89Y), 200 nM (113In), or 2 µM 1039 
(103Rh). Cells were randomly distributed across two 96-well plates, and about 0.3 million cells per well were 1040 
barcoded using a transient partial permeabilization protocol. Cells were washed once with 0.03% saponin 1041 
in PBS (Sigma Aldrich) prior to incubation in 200 µl barcoding reagent for 30 min at room temperature. 1042 
Cells were then washed four times with cell staining medium (CSM, PBS with 0.3% saponin, 0,5% bovine 1043 
serum albumin (Sigma Aldrich) supplemented with 2 mM EDTA (Stemcell Technologies) and pooled for 1044 
antibody staining. Two 126-well barcoding plates, with a set of standard samples on each plate, were used 1045 
for antibody staining with the tumor cell-centric and the immune cell-centric panels (Tables S3 and S4, 1046 
respectively). 1047 
 1048 
Antibodies and antibody labeling 1049 
All antibodies and corresponding clone, provider, and metal tag are listed in Tables S3 and S4. Target 1050 
specificity of the antibodies was confirmed in our laboratory. Antibodies were obtained in carrier/protein-1051 
free buffer or were purified using the Magne Protein A or G Beads (Promega) according to manufacturer's 1052 
instructions. Metal-labeled antibodies were prepared using the Maxpar X8 Multimetal Labeling Kit 1053 
(Fluidigm) according to manufacturer's instructions. After conjugation, the protein concentration was 1054 
determined using a Nanodrop (Thermo Scientific), and the metal-labeled antibodies were diluted in 1055 
Antibody Stabilizer PBS (Candor Bioscience) to a concentration of 200 or 300 µg/ml for long-term storage 1056 
at 4 °C. Optimal concentrations for antibodies were determined by titration, and antibodies were managed 1057 
using the cloud-based platform AirLab as previously described (Catena et al., 2016). 1058 
 1059 
Antibody staining and cell volume quantification 1060 
Antibody staining was performed on pooled samples after mass-tag cellular barcoding. The pooled 1061 
samples were incubated with FcR Blocking Reagent, human (Miltenyi Biotech) for 10 min at 4 °C and then 1062 
washed once with CSM. For staining with the immune cell-centric antibody panel (Table S3), cells were 1063 
incubated for 45 min at 4 °C followed by three washes with CSM. For staining with the tumor cell-centric 1064 
antibody panel (Table S4), purified rabbit anti-human ERα (Epitomics) was applied at 3 µg/ml for 45 min at 1065 
4 °C, and then samples were washed twice with CSM. Goat anti-rabbit IgG (Vector Labs) conjugated to 1066 
165Ho was then applied at 0.25 µg/ml for 45 min at 4 °C followed by two washes with CSM. The sample was 1067 
then stained with the remaining antibodies of the panel (Table S4) for 45 min at 4 °C followed by three 1068 
washes with CSM. For mass-based cell detection, cells were stained with 500 µM nucleic acid intercalator 1069 
iridium (191Ir and 193Ir, Fluidigm) in PBS with 1.6% PFA (Electron Microscopy Sciences) for 1 h at room 1070 
temperature or overnight at 4 °C. Cells were washed once with CSM and once with 0.03% saponin in PBS. 1071 
For cell volume quantification, cells were stained with 12.5 µg/ml Bis(2,2′-bipyridine)-4′-methyl-4-1072 
carboxybipyridine-ruthenium-N-succidimyl ester-bis(hexafluorophosphate) (96Ru, 98-102Ru, 104Ru, Sigma 1073 
Aldrich) in 0.1 M sodium hydrogen carbonate (Sigma Aldrich) for 10 min at room temperature as previously 1074 
described (Rapsomaniki et al., 2018). Cells were then washed twice with CSM, twice with 0.03% saponin in 1075 
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PBS, and twice with doubly distilled water (ddH2O). For mass cytometry acquisition, cells were diluted to 1076 
0.5 million cells/ml in ddH2O containing 10% EQTM Four Element Calibration Beads (Fluidigm) and filtered 1077 
through a 40-µm filter-cap FACS tube. Samples were placed on ice and introduced into the Helios 1078 
upgraded CyTOF2 (Fluidigm) using the Super Sampler (Victorian Airship) introduction system; data were 1079 
collected as .fcs files. 1080 
 1081 
Gadolinium contamination test 1082 
Some patients were scanned by magnetic resonance imaging for medical diagnosis and received a 1083 
gadolinium-based contrast agent. A small aliquot of each sample was tested for the presence of gadolinium 1084 
after fixation using mass cytometry. Gadolinium-positive cells were removed from data analysis by gating 1085 
(Figure S1C). 1086 
 1087 
Immunofluorescence imaging 1088 
We selected formalin-fixed paraffin embedded (FFPE) sections of breast cancer resectates for which mass 1089 
cytometry analysis has been performed on a different region of the same tumor. FFPE sections were 1090 
stained using the Opal 7-Color IHC Kit (PerkinElmer) according to manufacturer’s protocol. Briefly, slides 1091 
were deparaffinized, rehydrated, and antigen retrieved using Trilogy buffer (CellMarque) by autoclaving for 1092 
15 min. Slides were treated with 3% H2O2 for 15 min, washed, and blocked using 4% BSA/PBS/0.1% Triton 1093 
X-100 (all from Sigma). Primary antibodies and consecutive HRP-conjugated secondary antibodies (Table 1094 
S6) were diluted in 1% BSA/PBS/0.1% Triton X-100. Primary antibodies were incubated over night at 4 °C 1095 
and secondary antibodies were incubated for 1 h at room temperature. Slides were then incubated in 1096 
Amplification diluent containing a tyramide-conjugated fluorophore for 10 min. Prior to the next primary 1097 
antibody incubation, the slides were heated for 10 min in 10 mM citric acid, pH 6.0 at 95 °C to strip the 1098 
antibodies of the previous staining round. The protocol was repeated from the blocking step until a total of 1099 
six markers were co-stained. After the last staining round, the slides were washed, incubated with 0.5 1100 
µg/ml 4′,6 diamidine-2-phenylindole (DAPI; ThermoFischer) for 5 min, washed again, and mounted using 1101 
Prolong Diamond medium (ThermoFischer). The following set of markers was analyzed for each sample 1102 
(indicated in the order of staining): CTLA-4, PD-L1, PD-1, CD68, CD3e, PanK+EpCAM. Slides were 1103 
scanned using the multispectral imaging system Vectra 3.0 (PerkinElmer), and multispectral images were 1104 
analyzed using the InForm Cell Analysis software (PerkinElmer). Images were processed in Fiji and 1105 
contrast was enhanced to improve visibility. 1106 
 1107 
 1108 
QUANTIFICATION AND STATISTICAL ANALYSIS 1109 
 1110 
Mass cytometry data preprocessing 1111 
Mass cytometry data were concatenated using the .fcs File Concatenation Tool (Cytobank, Inc.), 1112 
normalized using the MATLAB version of the Normalizer tool (Finck et al., 2013), and debarcoded using the 1113 
CATALYST R/Bioconductor package (Chevrier et al., 2018). Debarcoded files were compensated for 1114 
channel crosstalk using single-stained polystyrene beads as previously described (Chevrier et al., 2018). 1115 
The compensated .fcs files were uploaded to the Cytobank server (Cytobank, Inc.) for manual gating on 1116 
populations of interest. For Figure 1, manual gates were set to exclude nonspecific background signal and 1117 
cisplatin-positive dead cells (Figure S1C). The resulting population was exported as .fcs files and loaded 1118 
into R (R Development Core Team, 2015) for downstream analysis. Sample duplicates that were used to 1119 
ensure high data quality between two barcoding plates (Figure S1D) were concatenated for downstream 1120 
analysis. 1121 
 1122 
Dimensionality reduction and clustering 1123 
For dimensionality reduction visualizations using the t-SNE algorithm (Van Der Maaten and Hinton, 2008), 1124 
signal intensities (dual counts) per channel were arcsinh-transformed with a cofactor of 5 (counts_transf = 1125 
asinh(x/5)). The R t-SNE package for Barnes-Hut implementation was used. For marker expression level 1126 
visualization on t-SNE plots, the expression was normalized between 0 and 1 to the 99th percentile and the 1127 
top percentile was set to 1. 1128 
 1129 
Exploration of batch effects 1130 
To assess the presence of batch effects in the data originating from possible confounding factors related to, 1131 
for example, sample origin or sample preparation, an approach based on principal component analysis was 1132 
followed, similar to the one proposed previously for high-throughput data analysis (Leek et al., 2010). 1133 
Initially, 1000 cells from each sample were randomly selected and then the principal components (PC) of 1134 
the multidimensional protein abundance measurements of these cells were computed. To assess how 1135 
much of the variability in the PCs was due to the actual protein measurements, the values of Spearman’s 1136 
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correlation coefficients between the two first PCs (in total 61% of variance explained) and all protein 1137 
measurements were computed (Figure S1F); values were highly correlated. To address the presence of 1138 
possible batch effects, the same process was repeated using all possible confounders (namely the 1139 
operator, barcoding plate, hospital of origin, date of sample receipt, and transport time). This time the 1140 
computed correlation values were negligible (Figure S1G), indicating absence of batch effects related to 1141 
sample origin or processing. 1142 
 1143 
Epithelial cell selection and immune cell type selection 1144 
To generate an in-depth phenotypic characterization of epithelial and immune cells, we applied 1145 
PhenoGraph (Levine et al., 2015), a state-of-the-art graph based clustering algorithm able to partition high-1146 
dimensional data into groups. Since the original data size was prohibitive in terms of computational 1147 
resources, a combined approach coupling artificial neural networks (ANNs) and PhenoGraph was 1148 
employed. We first created a representative cell pre-selection using a custom down sampling approach to 1149 
address the discrepancies in total numbers of cells per sample: for samples with less than 1000 cells, all 1150 
cells were considered; for samples between 1000 and 2000 cells, half of the cells were randomly sampled; 1151 
for samples between 2000 and 5000 cells, 30% of the cells were randomly selected; and for all other 1152 
samples, 20% of the cells were randomly selected. This down sampling scheme resulted in a dataset of 1153 
approximately 700,000 cells. This process balanced the discrepancies in terms of number of cells per 1154 
sample, while at the same time adequately representing all samples. All cells were clustered using 1155 
PhenoGraph, and the clusters were labeled as epithelial based on expression of one or more of the 1156 
following epithelial markers: EpCAM, E-Cadherin, pan cytokeratin, K5, K7, K8/K18, and/or K14 (Figure 1157 
S1M). All other cells were labeled as non-epithelial. This labeled dataset was used as input to train an ANN 1158 
classifier consisting of one hidden layer of 20 neurons (with a hyperbolic tangent sigmoid transfer function) 1159 
and one output layer of one neuron (with a softmax transfer function). The dataset was randomly split into 1160 
training (50%), validation (25%), and test (25%) sets. The ANN was trained using the scaled conjugate 1161 
gradient method (Moller, 1993), and its performance was evaluated using a standard cross-entropy 1162 
function. Training was terminated upon convergence after 254 epochs, when the ANN’s performance failed 1163 
to improve for 10 consecutive validation runs. The ANN’s performance on the test set indicated very high 1164 
concordance with the expert labeling with an overall accuracy of 99.5% (true positive rate of 99.1%, true 1165 
negative rate of 99.6%). The ANN was then applied to the remaining data. It successfully classified a total 1166 
of approximately 4 million cells as epithelial. The same down sampling scheme as above was employed to 1167 
limit their number to a computationally manageable subset of approximately 850,000 cells, which were 1168 
subsequently used for all downstream analysis. The same process was used for all immune cells (CD45+ 1169 
cells, Figure S2A), but this time, the cells were assigned to belong to eight different cluster types (T cells, 1170 
neutral killer cells, granulocytes, B cells, plasma cells, plamacytoid dendritic cells, myeloid cells, and 1171 
basophils) based on expression of immune cell type-specific markers (Figure S2D). The same ANN 1172 
settings were used, apart from the output layer, which consisted of eight nodes. The ANN’s performance on 1173 
the test set yielded an accuracy of 99.5%. All of the above computations were implemented using 1174 
MATLAB’s R2018a Neural Network Toolbox (MathWorks). For the heatmaps shown in Figures 2D, 2L, and 1175 
3C, clustering was performed on the abundance levels of the shown markers, using Spearman correlation 1176 
as a distance function and average linkage. The FAP and SMA gates used to identify different fibroblast 1177 
subsets in Figure S1P were estimated based on Costa et al., 2018. 1178 
 1179 
Clustering consensus 1180 
To address the inherent stochasticity of the used clustering algorithm, we performed an extensive 1181 
comparison between different PhenoGraph runs with different random initializations. We tested values of 1182 
parameter k (number of nearest neighbors) of 30 (default value, as recommended by the authors) and 100. 1183 
For each of these values of k, we executed PhenoGraph 100 times and computed the agreement between 1184 
different assignments using the adjusted Rand index (ARI) (Hubert and Arabie, 1985), a standard metric of 1185 
similarity between individual clustering runs. The ARI was computed between any two clustering 1186 
assignments to quantify the probability that a pair of cells were assigned to the same cluster (independently 1187 
of cluster label) in both runs, while additionally adjusting for chance. An ARI of 1 indicates identical cluster 1188 
outcomes, whereas values close to zero indicate random assignments. For the epithelial cells, the runs 1189 
with k=30 had a mean ARI of 0.63, and the runs with k=100 had a mean ARI of 0.81. Examination of all 1190 
pairwise agreements (Figure S3A) showed a few outliers. Without these outliers, the mean ARI was 1191 
approximately 0.85. For the rest of the analysis, we selected the clustering with the highest mean ARI as 1192 
the most representative. The ARI computations were implemented in Python using the module metrics in 1193 
the package scikit-learn. 1194 
 1195 
Quantification of phenotypic abnormality  1196 
To quantify how patterns found in tumor cells deviate from "normal” mammary cells, we used a novelty 1197 
detection method based on autoencoders. Autoencoders are a class of ANNs that attempt reconstruct their 1198 
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input by initially transforming the data to a lower-dimensional representation via an encoding function, and 1199 
then reconstruct the input from the compressed representation using a decoding function. Due to the 1200 
compression, the reconstruction is by definition lossy. Thus, the model learns to capture the most 1201 
prominent features and interdependencies that minimize information loss. We created an undercomplete, 1202 
dense autoencoder network and used as input a data matrix 𝑋, where the rows corresponded to the pool of 1203 
cells from juxta-tumoral tissue samples, and the columns to the 27 protein channels considered. The 1204 
network consisted of five layers of the following sizes: 27, 10, 2, 10, and 27. The dataset was randomly split 1205 
into training and validation (70%) and test (30%) sets, and the data was scaled to [0,1]. We used the 1206 
Rectified Linear Unit (ReLU) as a transfer function between all layers, apart from the output layer where a 1207 
softmax function was used to compress the output to the same dynamic range as the input. To evaluate the 1208 
performance of the reconstruction, we used a mean squared error (MSE) as a loss function: 1209 
 1210 
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where 𝑚  denotes the training samples, 𝑔≔𝑔9:,9;  the encoding functions, and 	𝑓 ≔𝑓9=,9>  the decoding 1213 
functions. We employed Adam (Kingma and Ba, 2014) as an optimizer with a batch size of 256; training 1214 
was terminated upon convergence with an early stopping criterion of ten epochs with no significant 1215 
decrease in the validation loss function (the maximum number of epochs was set to 500). The trained 1216 
network was able to create a reconstruction with high agreement with the real input with a median test set 1217 
MSE of 0.007. The model was implemented in Python using the neural network API Keras with a 1218 
TensorFlow backend. Once the network was trained, we fed it with the equivalent tumor single-cell data 1219 
and quantified MSE for each tumor cell. Since the autoencoder was trained to reconstruct patterns found in 1220 
juxta-tumoral tissue-derived cells, high values of MSE indicate strong deviations from normal. The median 1221 
MSE for each tumor served as a measure of tumor phenotypic abnormality from the average juxta-tumoral 1222 
tissue. We detected known normal luminal and basal cell phenotypes in our non-cancerous mammary 1223 
gland controls (Figure 3D) and observed a strong phenotypic overlap between juxta-tumoral tissue and 1224 
mammoplasty tissue (Figures 3B, 3C, and 4N), therefore we are confident that the non-cancerous juxta-1225 
tumoral tissue can be used as a “close-to-normal” control for comparisons with tumor We did not use the 1226 
four mammoplasty samples for training the autoencoder to determine tumor cell phenotypic abnormality, 1227 
because not enough mammoplasty tissue-derived cells were measured and the mammoplasty samples 1228 
contained very few basal cells. 1229 
 1230 
Tumor individuality 1231 
To assess tumor individuality, we devised a graph-based approach based on k-nearest neighbor (k-NN) 1232 
classification. We started with 𝑖 = 1,… , 𝑛 single cells that originated from 𝑐 = 1,… , 𝐶 samples. Each cell 1233 
was described by a multidimensional data vector 𝑥+ that contains the protein measurements, and its sample 1234 
ID 𝑌+ . Initially, a k-NN graph was constructed, where each cell was connected to the k=100 nearest 1235 
neighbors as computed using the Euclidean distance in the high-dimensional space. The probability that a 1236 
cell originated from sample 𝑐 was equal to the sample’s frequency in the dataset: 1237 
 1238 
𝑊G = HIJKH . 1239 
 1240 
Then, for each cell 𝑖 , we retrieved its 𝑘 = 100  nearest neighbors (𝑏+)  and their sample IDs (𝑌OP)  and 1241 
computed the posterior probability that cell 𝑖	originated from sample 𝑐 by assessing the neighbors’ votes, 1242 






The cell was assigned to the sample with the highest posterior (i.e., argmaxG 𝑝(𝑐|𝑥+)	), which was the sample 1246 
“voted” by the majority of its neighbors. Last, for all cells from the same sample, we computed the mean of 1247 





This step simply averaged the results so that we saw sample-to-sample probabilities and not cell-to-sample 1251 
probabilities, and it resulted in a 𝑐 × 𝑐 matrix, expressing similarities between samples based on patterns of 1252 
neighboring cells in the graph. Values on the diagonal of this matrix expressed how “self-contained” each 1253 
sample was in the graph and are referred to as the tumor individuality score. Values close to 1 indicate that 1254 
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the sample is localized within an isolated region of the graph, and smaller values indicate that the sample is 1255 
intermixed with cells from other samples. 1256 
 1257 
Chord diagram 1258 
Pairwise correlations between clusters were visualized as chord diagrams in R using the circlize package 1259 
(Gu et al., 2014). Links are shown for all cluster pairs with p<0.01 using Spearman correlation. 1260 
 1261 
Tumor grouping  1262 
To group the samples based on shared patterns in their ecosystem, we clustered the frequencies per 1263 
sample of all epithelial and immune clusters. The population frequencies quantify to which extent each 1264 
sample belongs to the different clusters and, as such, can be seen as a probability distribution across all 1265 
populations that sum to 1. For this reason, we employed the Jensen-Shannon divergence (JSD) as an 1266 
appropriate method of measuring the similarity between probability distributions. Here 𝑃, 𝑄 denotes the 1267 
probability density of samples 𝑝, 𝑞  over all populations. The JSD between samples 𝑝, 𝑞  is defined as 1268 
follows: 1269 
 1270 
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 1276 
In contrast to the KL divergence, the JSD is symmetric and bounded between 0 and 1. To cluster the 1277 
samples and populations, we used a hierarchical biclustering algorithm. Similarities between samples 1278 
based on their cluster assignments were computed using the JSD, similarities between clusters were 1279 
computed using a cosine distance metric, and an average linkage was used for both rows and columns. To 1280 
derive sample groups from the resulting dendrogram, we used a distance cutoff of 0.16. To identify the 1281 
populations responsible for the grouping, we used a feature selection/classification approach based on 1282 
random forests (Breiman, 2001). For each group considered, we created a dataset that included all 1283 
samples belonging to the group (class 1) and an equal number of samples from all other groups (class 0). 1284 
We fitted a random forest classifier with 1000 trees; in all cases, we were able to separate the classes with 1285 
reasonable accuracy. To identify how relevant each population was to the separation, we derived the 1286 
feature importance of all populations from the ensemble of trees. All methods were implemented in Python 1287 
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The mass cytometry data (.fcs files) and immunofluorescence images generated in this study are deposited 1294 
in Mendeley Data (http://dx.doi.org/10.17632/gb83sywsjc.1).  1295 
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Figure 1. A single-cell proteomic atlas of breast cancer ecosystems.  1297 
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Figure 2. The breast cancer immune landscape.  1301 
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Figure 3. Tumor cell phenotypic landscape in breast cancer.  1305 
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Figure 4. Molecular phenotypic abnormalities and tumor individuality are linked to features of poor 1309 
prognosis.  1310 
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Figure 5. Relationships in the tumor ecosystem correlate with features of disease progression.  1314 
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Figure 6. Breast tumors and their immunoenvironment are interwoven entities.  1318 
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